Armistice Capital Increases Stake in Citius Oncology, Inc. (CTOR) to 9.99%

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G/A (Amendment No. 3) for Citius Oncology, Inc. (CTOR). The filing reveals that the reporting persons have increased their position to 9,299,917 shares of Common Stock, up from a previous position of 8,078,404 shares. This holding represents 9.99% of the company's outstanding shares. Armistice Capital, LLC serves as the investment manager for the Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under the terms of their Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The event triggering this specific amendment occurred on March 31, 2026.